مورد إلكتروني
Liječenje nealkoholne masne bolesti jetre
| العنوان: | Liječenje nealkoholne masne bolesti jetre |
|---|---|
| عناروين إضافية: | Treatment of nonalcoholic fatty liver disease |
| المؤلفون: | Ivana Mikolašević, Sandra Milić, Lidija Orlić, Marija Stanić, Davor Štimac, Vojko Mavrinac, Vera Vlahović-Palčevski |
| المصدر: | Medicina Fluminensis : Medicina Fluminensis; ISSN 1847-6864 (Print); ISSN 1848-820X (Online); Volume 52; Issue 2 |
| بيانات النشر: | Croatian Medical Association, Branch Rijeka 2016 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Nealkoholna masna bolest jetre (engl. nonalcoholic fatty liver disease; NAFLD) najčešća je kronična bolest jetre danas. Jedna je od manifestacija metaboličkog sindroma, uz dijabetes, inzulinsku rezistenciju, debljinu, hiperlipidemiju i hipertenziju. NAFLD je klinički sindrom koji obuhvaća jednostavnu steatozu, nealkoholni steatohepatitis, fibrozu i cirozu jetre te hepatocelularni karcinom. Za sada ne postoji optimalna terapija nealkoholne masne bolesti jetre, liječenje se temelji na promjeni načina života, dijeti i tjelesnoj aktivnosti. Lijekovi za smanjenje inzulinske rezistencije, vitamini E i D te blokatori renin-angiotenzinaldosteron sustava pokazuju obećavajuće rezultate u pristupu pacijentu s NAFLD-om, ali njihova dugoročna učinkovitost i sigurnost primjene još uvijek nije znanstveno utemeljena. Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide. NAFLD is a liver manifestation of metabolic syndrome, along with hypertension, diabetes, dyslipidemia and insulin resistance. Nonalcoholic steatohepatitis (NASH) is a progressive form of NAFLD, which often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma. There is no optimal treatment for NAFLD and most treatment options are based on lifestyle changes, diet and physical activity. Medications that are reducing insulin resistance, vitamin E and D and renin-angiotensin-aldosterone system blockers have shown promising results, but their long-term effectiveness and safety remains to be established. |
| مصطلحات الفهرس: | metabolički sindrom; nealkoholna masna bolest jetre; terapija, metabolic syndrome X; non-alcoholic fatty liver disease; therapy, text, info:eu-repo/semantics/article, info:eu-repo/semantics/publishedVersion |
| URL: | |
| الإتاحة: | Open access content. Open access content info:eu-repo/semantics/openAccess Licence and rights statement: Medicina Fluminensis is an Open Access journal. The content of the Journal is available free of charge. Users are allowed to read, download, copy, redistribute, print, search and link to material, and alter, transform, or build upon the material, or use them for any other lawful purpose as long as they attribute the source in an appropriate manner according to the CC BY licence. Self-archiving policy: The papers published in Medicina Fluminensis can be deposited and self-archived in the institutional and thematic repositories providing the link to the journal's web pages and HRČAK. The Journal does not charge article processing charges (APC). Print version of the Journal: The print version of the Journal is distributed to members of the Croatian Medical Association – Rijeka Branch. Annual subscription fee in Croatia is 100 kn and is paid to the account no. 2360000-1400145092. Inquiries regarding advertising, subscription, reprints or previous issues should be addressed to: Hrvatski liječnički zbor – Podružnica Rijeka, Trg Republike Hrvatske 2/1, p.p.227, 51000 Rijeka, Hrvatska; e-mail: hlzrijeka@gmail.com. |
| ملاحظة: | application/pdf Croatian |
| أرقام أخرى: | HRCAK oai:hrcak.srce.hr:158496 1363243398 |
| المصدر المساهم: | HRCAK PORTAL ZNANSTVENIH CASOPISA REPUB From OAIster®, provided by the OCLC Cooperative. |
| رقم الأكسشن: | edsoai.on1363243398 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |